75 results about "EPA - Eicosapentaenoic acid" patented technology

The invention provides schizochytrium limacinum FJ-1 and application thereof in production of phospholipid type EPA (eicosapentaenoic acid). The application comprises the following steps: taking a cryopreserved schizochytrium limacinum strain, and inoculating the schizochytrium limacinum strain into a liquid seed culture medium for pre-culture; the method comprises the following steps: inoculating pre-cultured schizochytrium limacinum into a fermentation tank according to the inoculum size of 5-10% v / v, culturing for 48-60 hours at the sea salt concentration of 0.5-1% w / v, fermenting for 48-72 hours, supplementing sea salt to a culture medium in batches until the sea salt concentration is 3-5% w / v, and continuously culturing for 96-120 hours by controlling the glucose concentration and the yeast extract concentration through supplementing materials. The technical problem that the synthesis efficiency of schizochytrium limacinum phospholipid type EPA is low is solved through precise regulation and control of salinity stress, an efficient, economical and generalizable innovative scheme is provided for industrial production of functional lipid, and the method is suitable for large-scale production.

The invention belongs to the technical field of biology, and discloses a yarrowia lipolytica engineering strain for efficiently producing eicosapentaenoic acid based on citric acid metabolism regulation, a method and application of the yarrowia lipolytica engineering strain. Delta9 elongase, Delta8 desaturase, Delta5 desaturase and Delta17 desaturase genes in a fatty acid synthesis route, heterologous ATP-citrate lyase and a mitochondrial citric acid vector are overexpressed. According to the invention, ATP-citric acid lyase and a mitochondrial citric acid carrier gene which are respectively derived from Schizochylene sp. And Saccharomyces cerevisiae are jointly expressed in the yarrowia lipolytica engineering strain, so that the yields of EPA and grease in the yarrowia lipolytica engineering strain are remarkably improved, and compared with a control strain, the yields of the grease and the EPA are respectively improved by 243.35% and 161.85%.

The invention belongs to the technical field of biology, and discloses an exogenous cofactor enhanced yarrowia lipolytica strain, a method and application in efficient synthesis of EPA (eicosapentaenoic acid) and lipids.The chassis strain of the yarrowia lipolytica strain is yarrowia lipolytica Po1f, desaturase is partially prolonged in an overexpression fatty acid synthesis route in the strain, and the EPA and the lipids.The yield of the EPA and the lipids.The yield of the EPA and the lipids.The yield of the EPA and the lipids. The desaturase gene mainly comprises a delta 9 elongase gene, a delta 8 desaturase gene, a delta 5 desaturase gene and a delta 17 desaturase gene, and G6PDH and malic enzyme are overexpressed at the same time on the basis. The strain provided by the invention improves the EPA and lipid yield of yarrowia lipolytica; the method is suitable for constructing a genetic engineering strain with high yield of EPA and lipid, provides a basis for producing grease rich in EPA from yarrowia lipolytica, and solves the problems of non-sustainability, high cost and the like caused by obtaining EPA from fish.

The invention provides a method for separating EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) through supercritical fluid chromatography, and relates to the technical field of separation and purification. The invention provides a method for separating EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) by supercritical fluid chromatography, which comprises the following steps: by taking supercritical carbon dioxide and an organic reagent as mobile phases, and by utilizing the specific mobile phase property of supercritical CO2 after being mixed with the organic reagent (saturated aliphatic hydrocarbon) and matching with a normal-phase chromatographic column, separating the EPA from the DHA by supercritical fluid chromatography. A specific stationary phase (one or more of a silica gel surface bonded propylurea stationary phase, a silica gel surface bonded phenyl stationary phase and a silica gel surface bonded imidazolyl stationary phase) is adopted, effective separation and preparation of the EPA and the DHA in the fish oil can be achieved, the EPA and the DHA in the fish oil can be effectively separated within 50 min, the separation speed is high, the separation effect is good, and the method is suitable for industrial production. The purity of the obtained EPA and DHA is 98% or above, the purity of the EPA and the DHA is high, and the EPA and the DHA have good application prospects in the fields of medicine production and food and health care products.

The invention belongs to the technical field of skin care products, and discloses a quick-acting red-removing repair product which comprises the following components: water, caprylic / capric triglyceride, glycerol, sorbitol, phosphatidylcholine, 1, 3-propylene glycol, xanthan gum, eicosapentaenoic acid, docosahexaenoic acid, phytosphingosine, centella asiatica extract and tocopheryl acetate. A turmeric rhizome extract and 1, 2-hexanediol. Through mutual cooperation of the turmeric root extract and the centella asiatica extract, by taking enhancement of skin immune regulation and skin barrier functions as an action mechanism, on one hand, skin inflammatory response can be inhibited, and inflammation, microorganisms and bacteria can be effectively resisted, and on the other hand, skin barrier reconstruction can be promoted, wound healing can be promoted, and an ECM matrix can be protected; in addition, the eicosapentaenoic acid, the docosahexaenoic acid, the turmeric root extract, the phytosphingosine and the centella asiatica extract are wrapped by the nano-microcapsule liposome, so that the activity of the product can be ensured.

The invention belongs to the technical field of microbial engineering, and discloses a method for producing eicosapentaenoic acid (EPA) with high yield by schizochytrium limacinum based on random mutation and low-temperature screening and application, and the method comprises the following steps: driving overexpression of a G418 resistance gene through a P2520 promoter, constructing a random insertion mutant library, and screening to obtain a schizochytrium limacinum mutant strain with a randomly mutated genome; coating in a culture medium containing G418 resistance for culturing, and screening out strains which are resistant to low temperature and good in growth state at 15 DEG C; and inoculating into a fermentation culture medium, adding MgSO4 with the final mass concentration of 0.1% at the initial stage of fermentation, supplementing MnCl2 with the final mass concentration of 0.05% when fermentation is performed for 72 hours, and culturing to obtain a mutant strain. According to the invention, the G418 resistance gene carried by the plasmid is randomly inserted into the schizochytrium limacinum genome, and low-temperature induced screening is combined, so that the target limitation of traditional homologous recombination is broken through, and a stable strain with multiple mutation superposition can be obtained through enrichment.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

This description describes a method for treating pain by administering a pharmaceutical composition containing a therapeutically effective amount of margaric acid to a subject requiring pain treatment. Pharmaceutical compositions, such as topical and transdermal compositions, containing margaric acid and a pharmaceutically acceptable excipient are also described. A pain-relieving composition containing margaric acid, eicosapentaenoic acid, and a pharmaceutically acceptable excipient is further described.

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

The invention provides a method for producing polyunsaturated fatty acid, and belongs to the technical field of biological fermentation. The method for producing polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid from schizochytrium limacinum comprises the following steps: activating schizochytrium limacinum in a seed culture medium to obtain a schizochytrium limacinum seed culture solution; inoculating the schizochytrium limacinum seed culture solution into a fermentation culture medium for culturing, wherein the fermentation culture medium comprises rapeseed protein powder; and extracting the culture solution in the cultured fermentation culture medium to obtain the polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid. According to the present invention, the yield of polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid can be significantly improved.

Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10wt% and 50wt% polar lipids and between 45wt% and 60wt% fatty acids, wherein the fatty acids comprise more than 10wt% of eicosapentaenoic acid (EPA) as triglyceride conjugates and / or diglyceride conjugates, and less than 15wt% EPA as free fatty acids. EPA level may reach up to 90wt%, and the botanical extract may be fluid at room temperature. Growth conditions are configured, adjusted and monitored to promote EPA formation in the cell vacuoles, resulting in a high proportion of EPA as tri / di-glyceride conjugates, as well as in a high concentration of Ω-3 fatty acids, which merely requires gentle extraction procedures to reach the final products, thereby maintaining the biochemical of the compounds without excessive modifications.

The application belongs to the technical field of biology, and discloses a Yarrowia lipolytica engineering strain for efficiently producing eicosapentaenoic acid based on citric acid metabolism regulation, a method and application, wherein a chassis strain of the engineering strain is Yarrowia lipolytica Po1f, and genes of Δ9 elongase, Δ8 desaturase, Δ5 desaturase and Δ17 desaturase in a fatty acid synthesis pathway, a heterologous ATP-citrate lyase and a mitochondrial citrate carrier are overexpressed. ATP-citrate lyases and mitochondrial citrate carrier genes respectively derived from Schizochytrium sp. and Saccharomyces cerevisiae are combined to be expressed in the Yarrowia lipolytica engineering strain, so that the production of EPA and oil in the Yarrowia lipolytica engineering strain is significantly improved, and compared with a control strain, the production of oil and EPA is respectively increased by 243.35% and 161.85%.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The invention relates to the technical field of prevention and control of aquatic diseases, in particular to a preparation method of a pelteobagrus fulvidraco intestinal inflammation composite regulation preparation containing omega-3 fatty acid-lipoxin-phospholipid. The composite regulation and control preparation is prepared from the following functional components: 20 to 30 parts of eicosapentaenoic acid, 0.1 to 0.5 part of lipoxin B4, 8 to 12 parts of phosphatidylserine, 1 to 2 parts of dehydroabietic acid, 10 to 18 parts of sophorobiose and 0.01 to 0.03 part of ethoxyquin. The product integrates the functions of resisting bacteria, promoting inflammation regression and promoting tissue repair through a multi-target synergistic mechanism to construct a complete inflammation regulation and control pathway; meanwhile, by virtue of a nano-liposome dosage form technology, the active ingredients are effectively protected; the product is completely compounded from natural components to realize an antibacterial effect. According to the technical scheme, the technical problems of low antibacterial efficiency, single action mechanism, insufficient mucous membrane repair capability and the like of the existing prevention and control technology for the intestinal inflammation of the pelteobagrus fulvidraco can be solved, and the pelteobagrus fulvidraco has an ideal application prospect.

The invention provides a recombinant yarrowia lipolytica strain with high yield of eicosapentaenoic acid as well as a construction method and application of the recombinant yarrowia lipolytica strain, and belongs to the technical field of genetic engineering. The invention provides a recombinant yarrowia lipolytica strain Po1f: Y1 capable of reconstructing an EPA (eicosapentaenoic acid) synthetic route, and the recombinant yarrowia lipolytica strain Po1f: Y2 is constructed by taking the recombinant yarrowia lipolytica strain Po1f: Y1 as a host and overexpressing an LPCAT (Low Performance Protein Amino Transferase) mutant; and knocking out encoding genes such as PEX10, GUT2, TGL4, SNF1 and the like, and combining with overexpressed DGAT1 and the like to obtain a recombinant yarrowia lipolytica strain Po1f: Y3 with high yield of EPA. The recombinant yarrowia lipolytica strain Po1f: Y3 strain EPA accounts for 50% of the relative content of total fatty acid, the oil content accounts for 48% of the weight of stem cells, and the biomass of recombinant yeast in a 7.5 L fermentation tank exceeds 100 g stem cell weight / L.

Disclosed herein are pet food compositions for treating or preventing-inter alia-struvite urolithiasis comprising at least one of caprylic acid and capric acid; and at least one of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).

The invention discloses a sustainable asphalt regenerant, a preparation method and application, the sustainable asphalt regenerant comprises methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, methyl eicosenoate, methyl arachidonate and the like, the content of saturated fatty acid methyl ester exceeds 21.3-25.6% of the total content of fatty acid methyl ester, and the content of saturated fatty acid methyl ester exceeds 21.3-25.6% of the total content of fatty acid methyl ester. The content of unsaturated fatty acid methyl ester exceeds 66.2-70.5% of the total content of fatty acid methyl ester, and the total fraction is 100%; the regenerant is prepared from waste edible oil and fat as a raw material, and compared with a traditional petroleum-based regenerant, the regenerant is wide in source, low in raw material cost and renewable. The sustainable asphalt regenerant can effectively recover various properties of aged asphalt, and solves the problems of poor water damage resistance and durability caused by high content of acidic compounds in the existing waste edible oil asphalt regenerant; meanwhile, the recovery and reutilization of the waste edible grease and the aged asphalt material are realized.

The present invention provides for a water-soluble composition comprising at least one source of Omega-3 comprising at least one Omega-3 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and alpha-linolenic acid (ALA), and micelle-promoting agents comprising one or more of carrier oils, solvents, emulsiiiers and antioxidants, in order to promote an increase in biovailability of the Omega-3 Source of at least two times.

A composition containing 96-99% by area of an eicosapentaenoic acid alkyl ester, the content of an arachidonic acid alkyl ester being 0.7% by area or less, and the content of a mono-trans body of the eicosapentaenoic acid alkyl ester being 2.5% by area or less. A method for producing a composition containing an eicosapentaenoic acid alkyl ester at a high concentration, the method comprising: subjecting a composition containing an eicosapentaenoic acid alkyl ester obtained by alkyl esterification of a raw oil containing eicosapentaenoic acid to precision distillation at a vacuum degree of 0.2 Torr or less and a temperature of 190 DEG C or less in the entire column; and performing concentration treatment on the composition after precision distillation by using chromatography.

The present application relates to the technical field of aquatic disease prevention and control, and particularly relates to a preparation method of a compound regulator for enteron inflammation of Pelteobagrus fulvidraco containing omega-3 fatty acid-lipoxin-phospholipid. The functional components of the compound regulator include eicosapentaenoic acid 20-30 parts, lipoxin B4 0.1-0.5 parts, phosphatidylserine 8-12 parts, dehydroabietic acid 1-2 parts, sophorobiose 10-18 parts and ethoxyquinoline 0.01-0.03 parts. The product integrates the functions of antibiosis, inflammation subsiding and tissue repair through a multi-target synergistic mechanism, and builds a complete inflammation regulation pathway. Meanwhile, the active ingredients are effectively protected by means of nano-liposome dosage form technology. The product realizes the antibiosis function by using natural ingredients. The technical scheme can solve the technical problems of low antibiosis efficiency, single mechanism and insufficient mucosal repair capacity of the existing prevention and control technology for enteron inflammation of Pelteobagrus fulvidraco, and has an ideal application prospect.

The invention relates to nannochloropsis oculata SH2 as well as a screening method and application thereof, and belongs to the technical field of microorganisms. The nannochloropsis oculata SH2 is preserved in the China Center for Type Culture Collection on June 19, 2025, and the preservation number of the nannochloropsis oculata SH2 is CCTCC (China Center for Type Culture Collection) NO: 20251433. The nannochloropsis oculata SH2 disclosed by the invention is rich in long-chain polyunsaturated fatty acid, and can be used for simultaneously producing various high-value products such as EPA (eicosapentaenoic acid) and ARA (arachidonic acid), so that the comprehensive utilization value and economical efficiency of the SH2 are greatly improved, and a foundation is laid for developing compound nutrient products for different people.

A composition is provided comprising an effective amount of a combination of gamma linolenic acid (GLA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). The composition comprises about 5% w / w to about 25% w / w GLA, and about 5% w / w to about 25% w / w of a mixture of DHA and EPA. Methods of modulating fatty acid profiles or treating an inflammatory condition in a horse include administering an effective amount of the composition to the horse. The inflammatory conditions capable of being treated include gastric ulcers, airway inflammation, joint inflammation, or combinations thereof.

This present invention relates to the use of eicosapentaenoic acid (EPA) for treating and reducing the negative effects of respiratory virus including coronaviruses and particularly the novel coronavirus-19 (COVID-19). Notably, the eicosapentaenoic acid in the free fatty acid (EPA-FFA) form has a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99%. Specifically, the EPA-FFA exhibits a reduction of expressed interleukins, such as IL-6, reduction in D-dimers and a reduction relating to the release of AA.

The invention relates to a rapid excavation technology for phosphatidylcholine type DHA / EPA and phosphatidyl ethanolamine type DHA / EPA based on mass spectrum dual-mode multiple characteristics, and belongs to the field of research on chemical components of aquatic products. Phospholipid-type EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) components have wide pharmacological activity and good bioavailability, mainly exist in aquatic products such as fishes, shrimps, shellfish and algae, are important nutrient elements which are indispensable to human bodies but cannot be synthesized by themselves, have indispensable effects on human health, and can be used for preparing health-care food. Wherein phosphatidylcholine type DHA / EPA (PCEPA / DHA) and phosphatidyl ethanolamine type DHA / EPA (PEEPA / DHA) are reported at most. According to the method, the krill oil and the fish oil are analyzed by adopting a liquid chromatography-tandem high-resolution mass spectrometry technology, a plurality of mass spectrometry characteristics of positive and negative ion dual modes and python programming are fused to construct a rapid mining algorithm, PCEPA / DHA and PEEPA / DHA in the krill oil and the fish oil are discovered, and an effective technical support is provided for deep discovery, development and utilization of high-value phospholipid DHA and EPA in the krill oil and the fish oil.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The present disclosure relates to a food composition including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) for use in a method for treating and / or preventing a chronic inflammatory joint disease in a companion animal, particularly a canine or a feline, in need thereof, wherein the mass ratio of EPA to DHA is from about 0.2:1 to about 1:1, and the total amount of EPA and DHA is from about 0.1 g / Mcal to about 20 g / Mcal.

The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.

The invention provides a schizochytrium limacinum strain Schizochytrium sp. ABBS-E11 with high EPA (Eicosapentaenoic Acid) content, and a preparation method of the schizochytrium limacinum strain. The strain is preserved in the China Center for Type Culture Collection, the preservation number of the strain is CCTCC NO: M 20251165, and the preservation date is May 23, 2025. The mutant strain is obtained through separation, mutagenesis and screening, and compared with schizochytrium limacinum in the prior art, the EPA content in a product is remarkably increased, high biomass and titer are kept, and the absolute yield of EPA is increased. The invention further provides a method for producing grease rich in EPA through fermentation of the schizochytrium limacinum mutant strain. According to the method, a standard fermentation process is adopted, no special medicine or reagent needs to be added, the safety performance is guaranteed, and the method has important significance on industrial application. Moreover, the grease rich in EPA prepared by adopting the strain also contains more than 35% of DHA and lower DPA, so that the grease not only has double nutritional values, but also is convenient to separate and purify, and has huge market value.

The invention provides an SNP molecular marker related to meat pigeon unsaturated fatty acid EPA and application of the SNP molecular marker, and belongs to the technical field of molecular markers. The invention discloses an SNP (Single Nucleotide Polymorphism) molecular marker related to meat pigeon unsaturated fatty acid EPA (Eicosapentaenoic Acid), the SNP molecular marker is located at the 101st site on a DNA (Deoxyribonucleic Acid) fragment as shown in SEQ ID No.1, and a mutant gene is G or A. Through genotyping of a population level and determination of the content of muscle EPA, it is found that SNP mutation is significantly related to the content of EPA in meat pigeon muscles, and the muscle EPA level of a carrier of a mutant allele (A / A) is generally higher than that of a wild allele individual. The invention shows that the site can be used as a functional molecular marker closely related to the nutritional traits of the EPA of the pigeon meat, and has potential molecular breeding value.

Disclosed herein are pet food compositions for treating or preventing—inter alia—struvite urolithiasis comprising at N least one of caprylic acid and capric acid; and at least one of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).